Episode 86: Pimavanserin and Atypical Antipsychotics to Treat Parkinson Disease Psychosis
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Dilesh Doshi, PharmD. [LISTEN TIME: 22 minutes]
Episode 86 of the NeurologyLive®
The Mind Moments® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 86, "Pimavanserin and Atypical Antipsychotics to Treat Parkinson Disease Psychosis," features an exclusive interview with Dilesh Doshi, PharmD, vice president of Health Economics and Outcomes Research at Acadia Pharmaceuticals. He spoke on the advantages and benefits of pimavanserin (Nuplazid; Acadia), the only FDA-approved therapy to treat Parkinson disease psychosis. Additionally, he discussed recent data that compared efficacy and safety of other off-label therapies such as clozapine and quetiapine.
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Tiziana Announces Planned Phase 2 Study of Foralumab in Progressive Multiple Sclerosis Blarcamesine Deemed Safe, Effective in Phase 2 Extension Study of Parkinson Disease Dementia Eplontersen Continues to Show Clinical Benefit in Long-Term Analysis of hATTR Polyneuropathy Reldesemtiv to be Discontinued in ALS Following Data Monitoring Committee Analysis
EPISODE BREAKDOWN
- 1:10 – Mechanistic differences between pimavanserin and other atypical antipsychotics
- 3:00 – Understanding drug-to-drug interactions for PDP
- 5:05 – Decision-making with quetiapine and negative cognitive effects
- 7:10 – Improved use of pimavanserin since approval
- 9:00 – Neurology News Minute
- 11:40 – Potential predictors of mortality in Parkinson disease psychosis
- 15:20 – Possibility of preventing PD psychosis
- 17:20 – Future research on identifying subgroups of responders to treatment
Hoping to listen on your favorite podcast app? See below:
REFERENCE
1. Yunusa I, Rashid N, Rajagopalan K, et al. Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson’s disease psychosis: systematic review and network meta-analysis. J Geriatr Psychiatry Neurol. Published online January 31, 2023. doi:10.1177/08919887231154933
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
